Migraine Drugs Market byType (Abortive Medicine, Preventive Medicine), Administration Route (Oral, Injection, Others), Distribution Channel (Hospital-based Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

Migraine Drugs Market

Industry:  Life Sciences & Healthcare | Publish Date: Mar 2020 | No of Pages:  408 | No. Tables:  236 | No. Figures:  206

Market Definition:

The global Migraine Drugs Market size was valued at USD 1.80 billion in 2019 and is predicted to reach USD 2.44 billion by 2030, with a CAGR of 2.8% from 2020-2030.

Migraine is a medical condition pertaining with primary headache disorder with symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound. The headaches start from one side of the head and are pulsating in nature. In some cases, patients are affected by prevalence of aura.

The recurrent headaches can last up to some hours or days, with intensity varying from moderate to severe. Migraine has no permanent cure, but migraine drugs can be used to reduce and prevent migraines.

Women are more prone to migraine attacks due to conditions like; menstrual migraines, menopause migraines, and migraines due to stress, hypertension, or other hormonal issues. The increasing prevalence of migraine, specifically in women as compared to men, raises the demand for effective migraine drugs, thereby propagating the growth of global migraine drugs market.

Market Dynamics and Trends:

According to the data provided by Migraine Trust in 2017, 1 in 7 people worldwide suffer from migraine, i.e. 2% of the total world population suffer from migraine; thereby, migraine being the third most common disease at global level. This scenario generates a demand for effective migraine drugs with minimal or no side-effects; hence supplementing the growth of migraine drugs market.

However, side effects associated with the intake of migraine drugs are expected to restrict the growth of migraine drugs market.

Moreover, the factors such as growing consumer awareness regarding better treatment options, increasing number of approvals granted by the U.S Food and Drug Administration, and upsurge in investments for R&D activities, are anticipated in creating several profitable opportunities for the growth of global migraine drugs market, in coming future.

 

Market Segmentations and Scope of the Study:

The global migraine drugs market share has been analyzed based on type, route of administration, distribution channel and geography. Based on type, the migraine drugs market is segmented into preventive medicine and abortive medicine. The abortive medicine segment is sub segmented into Triptans (Serotonin Receptor Agonists), Ergotamine Derivative, and others. The preventive medicine is further divided into Anticonvulsant, Antidepressant, Beta Blocker, and others. Based on distribution channel, the migraine drugs market is divided into hospital-based pharmacies, retail pharmacies, and online pharmacies. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

 

Geographical Analysis:

North America denotes higher adoption of the migraine drugs and is anticipated to hold the highest market share in the global migraine drugs market throughout the forecast period. This is attributable to the factors including presence of well-established healthcare amenities, increased awareness among people, and advancements in medical technologies.

Asia Pacific is estimated to show rapid growth with developing market size, owing to increasing accessibility to healthcare facilities, and increased investment by the market players especially in the emerging economies.

 

Competitive Landscape:

The migraine drugs market is highly competitive and consists of various market players. Some of the major market players include Allergan Plc., Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA, and Novartis International AG, among others.

An upsurge in R&D activities and increasing approvals granted by the U.S Food and Drug Administration (FDA), for new products launched by the key players, is leading the healthcare industry to new heights, thereby creating lucrative opportunities in the global migraine drugs market.

For instance, in January 2020, Ubrogepant commercialized as Ubrelvy in the migraine drugs market was granted the FDA approval, for treating patients suffering from acute migraine with or without the prevalence of aura in adults. Ubrogepant as compared to its antagonist placebo gives fast relief from migraine symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound; within 2 hours of intake.

In February 2020, Biohaven announced that its NURTEC ODT-Rimegepant drug got approved by the U.S FDA, for treatment of acute migraine in adults. The studies claimed that a single oral dose of 75 mg NURTEC ODT, can provide relief to patients suffering from acute migraine condition within an hour, and its effect lasts for about 48 hours. The first-ever Calcitonin Gene-Related Peptide (CGRP) receptors, are orally dispersible tablets, that can be taken with or without water. These are known to provide fast relief even in acute migraine conditions.

In February 2020, Lundbeck, a well-known player in the migraine drugs market announced that its drug VYEPTI- eptinezumab-jjmr, got approved by the U.S FDA, for prevention and treatment of migraine in adults. VYEPTI is the first-ever intravenous (IV) treatment for migraine prevention. The clinical studies represented migraine reduction by 75% in 6 months, with a recommended dosage of 100 mg every 3 months.

KEY BENEFITS:

  • The migraine drugs market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the migraine drugs market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The report provides detailed information related to key drivers, restraints, opportunities, and their impact on the migraine drugs market is provided in the report.

  • The report incorporates competitive analysis of the market players along with their market share in the global migraine drugs market.

  • The SWOT analysis and Porters Five Forces model is elaborated in the study of migraine drugs market.

  • Value chain analysis in the migraine drugs market study provides a clear picture of the stakeholders’ roles.

KEY MARKET SEGMENTS:

By Type

  • Abortive Medicine

    • Triptans (Serotonin Receptor Agonists)

    • Ergotamine Derivative

    • Others

  • Preventive Medicine

    • Anticonvulsant

    • Antidepressant

    • Beta Blocker

    • Others

By Route of Administration

  • Oral

  • Injection

  • Others

By Distribution Channel

  • Hospital-Based Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • RoW

    • Saudi Arabia

    • South Africa

    • Brazil

    • Remaining countries

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Analysis Period

2019–2030

Base Year Considered

2020

Forecast Period

2020–2030

Market Size Estimation

Billion (USD)

Market Segmentation

By Type (Abortive Medicines, Preventive Medicines) By Route of Administration (Oral, Injection, Other Routes) By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographical Segmentation

North America (U.S., Canada, Mexico) Europe (UK, Germany, Italy, Spain, France, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of APAC), Rest of the World (Brazil, South Africa, Saudi Arabia, Remaining Countries)

Companies Profiled

Allergan Plc., Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA, and Novartis International AG.

column chart pie chart

1.     INTRODUCTION

1.1.           REPORT DESCRIPTION

1.2.           Research Methodology

1.2.1             Secondary Research

1.2.2             Data Analysis Framework

1.2.3             Market size estimation

1.2.4             Forecasting

1.2.5             Primary Research and Data Validation

2.      MARKET SNAPSHOT, 2019-2030 Million USD

2.1.           MARKET SNAPSHOT

3.      PORTER’S FIVE FORCE MODEL ANALYSIS

4.      MARKET DYNAMICS

4.1.           GROWTH DRIVERS

4.1.1             DRIVER 1

4.1.2             DRIVER 2

4.1.3             DRIVER 3

4.1.4             DRIVER 4

4.2.           CHALLENGES

4.2.1             CHALLENGE 1

4.2.2             CHALLENGE 2

4.3.           OPPORTUNITIES

4.3.1             OPPORTUNITY 1

4.3.2             OPPORTUNITY 2

5.      GLOBAL MIGRAINE Drugs Market, By Type

5.1.           Overview

5.2.           Abortive Medicines

5.2.1             Global Abortive Medicines Market, By Type

5.2.1.1        Triptans Market, By Region

5.2.1.1.1        North America Triptans Market, By Country

5.2.1.1.2        Europe Triptans Market, By Country

5.2.1.1.3        Asia-Pacific Triptans Market, By Country

5.2.1.1.4        Rest of World Triptans Market, By Country

5.2.1.2        Ergotamine Derivatives Market, By Region

5.2.1.2.1        North America Ergotamine Derivatives Market, By Country

5.2.1.2.2        Europe Ergotamine Derivatives Market, By Country

5.2.1.2.3        Asia-Pacific Ergotamine Derivatives Market, By Country

5.2.1.2.4        Rest of World Ergotamine Derivatives Market, By Country

5.2.1.3        Other Abortive Medicine Market, By Region

5.2.1.3.1        North America Other Abortive Medicine Market, By Country

5.2.1.3.2        Europe Other Abortive Medicine Market, By Country

5.2.1.3.3        Asia-Pacific Other Abortive Medicine Market, By Country

5.2.1.3.4        Rest of World Other Abortive Medicine Market, By Country

5.2.2             Abortive Medicines Market, By Region

5.2.2.1        North America Abortive Medicines Market, By Country

5.2.2.2        Europe Abortive Medicines Market, By Country

5.2.2.3        Asia-Pacific Abortive Medicines Market, By Country

5.2.2.4        Rest of World Abortive Medicines Market, By Country

5.3.           Preventive Medicines

5.3.1             Global Preventive Medicines Market, By Type

5.3.1.1        Anticonvulsants Market, By Region

5.3.1.1.1        North America Anticonvulsants Market, By Country

5.3.1.1.2        Europe Anticonvulsants Market, By Country

5.3.1.1.3        Asia-Pacific Anticonvulsants Market, By Country

5.3.1.1.4        Rest of World Anticonvulsants Market, By Country

5.3.1.2        Antidepressants Market, By Region

5.3.1.2.1        North America Antidepressants Market, By Country

5.3.1.2.2        Europe Antidepressants Market, By Country

5.3.1.2.3        Asia-Pacific Antidepressants Market, By Country

5.3.1.2.4        Rest of World Antidepressants Market, By Country

5.3.1.3        Beta Blockers Market, By Region

5.3.1.3.1        North America Beta Blockers Market, By Country

5.3.1.3.2        Europe Beta Blockers Market, By Country

5.3.1.3.3        Asia-Pacific Beta Blockers Market, By Country

5.3.1.3.4        Rest of World Beta Blockers Market, By Country

5.3.1.4        Other Preventive Medicines Market, By Region

5.3.1.4.1        North America Other Preventive Medicines Market, By Country

5.3.1.4.2        Europe Other Preventive Medicines Market, By Country

5.3.1.4.3        Asia-Pacific Other Preventive Medicines Market, By Country

5.3.1.4.4        Rest of World Other Preventive Medicines Market, By Country

5.3.2             Preventive Medicines Market, By Region

5.3.2.1        North America Preventive Medicines Market, By Country

5.3.2.2        Europe Preventive Medicines Market, By Country

5.3.2.3        Asia-Pacific Preventive Medicines Market, By Country

5.3.2.4        Rest of World Preventive Medicines Market, By Country

6.      Global  Migraine Drugs Market, By Route of Administration

6.1.           Overview

6.2.           Oral

6.2.1             Oral Market, By Region

6.2.1.1        North America Oral Market, By Country

6.2.1.2        Europe Oral Market, By Country

6.2.1.3        Asia-Pacific Oral Market, By Country

6.2.1.4        Rest of World Oral Market, By Country

6.3.           Injection

6.3.1             Injection Market, By Region

6.3.1.1        North America Injection Market, By Country

6.3.1.2        Europe Injection Market, By Country

6.3.1.3        Asia-Pacific Injection Market, By Country

6.3.1.4        Rest of World Injection Market, By Country

6.4.           Other Routes

6.4.1             Other Routes Market, By Region

6.4.1.1        North America Other Routes Market, By Country

6.4.1.2        Europe Other Routes Market, By Country

6.4.1.3        Asia-Pacific Other Routes Market, By Country

6.4.1.4        Rest of World Other Routes Market, By Country

7.      Global  Migraine Drugs Market, By Distribution Channel

7.1.           Overview

7.2.           Retail Pharmacies

7.2.1             Retail Pharmacies Market, By Region

7.2.1.1        North America Retail Pharmacies Market, By Country

7.2.1.2        Europe Retail Pharmacies Market, By Country

7.2.1.3        Asia-Pacific Retail Pharmacies Market, By Country

7.2.1.4        Rest of World Retail Pharmacies Market, By Country

7.3.           Hospital Pharmacies

7.3.1             Hospital Pharmacies Market, By Region

7.3.1.1        North America Hospital Pharmacies Market, By Country

7.3.1.2        Europe Hospital Pharmacies Market, By Country

7.3.1.3        Asia-Pacific Hospital Pharmacies Market, By Country

7.3.1.4        Rest of World Hospital Pharmacies Market, By Country

7.4.           Online Pharmacies

7.4.1             Online Pharmacies Market, By Region

7.4.1.1        North America Online Pharmacies Market, By Country

7.4.1.2        Europe Online Pharmacies Market, By Country

7.4.1.3        Asia-Pacific Online Pharmacies Market, By Country

7.4.1.4        Rest of World Online Pharmacies Market, By Country

8.      Global  Migraine Drugs Market, By Region

8.1.           Overview

8.2.           North America

8.2.1             North America Migraine Drugs Market, By Type

8.2.1.1        North America  Abortive Medicines Market, By Type

8.2.1.2        North America  Preventive Medicines Market, By Type

8.2.2             North America Migraine Drugs Market, By Route of Administration

8.2.3             North America Migraine Drugs Market, By Distribution Channel

8.2.4             North America Migraine Drugs, Market By Country

8.2.4.1        U.S.

8.2.4.1.1        U.S. Migraine Drugs Market, By Type

8.2.4.1.1.1. U.S. Abortive Medicines Market, By Type

8.2.4.1.1.2. U.S. Preventive Medicines Market, By Type

8.2.4.1.2        U.S. Migraine Drugs Market, By Route of Administration

8.2.4.1.3        U.S. Migraine Drugs Market, By Distribution Channel

8.2.4.2        Canada

8.2.4.2.1        Canada Migraine Drugs Market, By Type

8.2.4.2.1.1. Canada Abortive Medicines Market, By Type

8.2.4.2.1.2. Canada Preventive Medicines Market, By Type

8.2.4.2.2        Canada Migraine Drugs Market, By Route of Administration

8.2.4.2.3        Canada Migraine Drugs Market, By Distribution Channel

8.2.4.3        Mexico

8.2.4.3.1        Mexico Migraine Drugs Market, By Type

8.2.4.3.1.1. Mexico Abortive Medicines Market, By Type

8.2.4.3.1.2. Mexico Preventive Medicines Market, By Type

8.2.4.3.2        Mexico Migraine Drugs Market, By Route of Administration

8.2.4.3.3        Mexico Migraine Drugs Market, By Distribution Channel

8.3.           Europe

8.3.1             Europe Migraine Drugs Market, By Type

8.3.1.1        Europe  Abortive Medicines Market, By Type

8.3.1.2        Europe  Preventive Medicines Market, By Type

8.3.2             Europe Migraine Drugs Market, By Route of Administration

8.3.3             Europe Migraine Drugs Market, By Distribution Channel

8.3.4             Europe Migraine Drugs, Market By Country

8.3.4.1        Germany

8.3.4.1.1        Germany Migraine Drugs Market, By Type

8.3.4.1.1.1. Germany Abortive Medicines Market, By Type

8.3.4.1.1.2. Germany Preventive Medicines Market, By Type

8.3.4.1.2        Germany Migraine Drugs Market, By Route of Administration

8.3.4.1.3        Germany Migraine Drugs Market, By Distribution Channel

8.3.4.2        UK

8.3.4.2.1        UK Migraine Drugs Market, By Type

8.3.4.2.1.1. UK Abortive Medicines Market, By Type

8.3.4.2.1.2. UK Preventive Medicines Market, By Type

8.3.4.2.2        UK Migraine Drugs Market, By Route of Administration

8.3.4.2.3        UK Migraine Drugs Market, By Distribution Channel

8.3.4.3        France

8.3.4.3.1        France Migraine Drugs Market, By Type

8.3.4.3.1.1. France Abortive Medicines Market, By Type

8.3.4.3.1.2. France Preventive Medicines Market, By Type

8.3.4.3.2        France Migraine Drugs Market, By Route of Administration

8.3.4.3.3        France Migraine Drugs Market, By Distribution Channel

8.3.4.4        Italy

8.3.4.4.1        Italy Migraine Drugs Market, By Type

8.3.4.4.1.1. Italy Abortive Medicines Market, By Type

8.3.4.4.1.2. Italy Preventive Medicines Market, By Type

8.3.4.4.2        Italy Migraine Drugs Market, By Route of Administration

8.3.4.4.3        Italy Migraine Drugs Market, By Distribution Channel

8.3.4.5        Spain

8.3.4.5.1        Spain Migraine Drugs Market, By Type

8.3.4.5.1.1. Spain Abortive Medicines Market, By Type

8.3.4.5.1.2. Spain Preventive Medicines Market, By Type

8.3.4.5.2        Spain Migraine Drugs Market, By Route of Administration

8.3.4.5.3        Spain Migraine Drugs Market, By Distribution Channel

8.3.4.6        Rest of Europe

8.3.4.6.1        Rest of Europe Migraine Drugs Market, By Type

8.3.4.6.1.1. Rest of Europe Abortive Medicines Market, By Type

8.3.4.6.1.2. Rest of Europe Preventive Medicines Market, By Type

8.3.4.6.2        Rest of Europe Migraine Drugs Market, By Route of Administration

8.3.4.6.3        Rest of Europe Migraine Drugs Market, By Distribution Channel

8.4.           Asia-Pacific

8.4.1             Asia-Pacific Migraine Drugs Market, By Type

8.4.1.1        Asia-Pacific  Abortive Medicines Market, By Type

8.4.1.2        Asia-Pacific  Preventive Medicines Market, By Type

8.4.2             Asia-Pacific Migraine Drugs Market, By Route of Administration

8.4.3             Asia-Pacific Migraine Drugs Market, By Distribution Channel

8.4.4             Asia-Pacific Migraine Drugs, Market By Country

8.4.4.1        China

8.4.4.1.1        China Migraine Drugs Market, By Type

8.4.4.1.1.1. China Abortive Medicines Market, By Type

8.4.4.1.1.2. China Preventive Medicines Market, By Type

8.4.4.1.2        China Migraine Drugs Market, By Route of Administration

8.4.4.1.3        China Migraine Drugs Market, By Distribution Channel

8.4.4.2        India

8.4.4.2.1        India Migraine Drugs Market, By Type

8.4.4.2.1.1. India Abortive Medicines Market, By Type

8.4.4.2.1.2. India Preventive Medicines Market, By Type

8.4.4.2.2        India Migraine Drugs Market, By Route of Administration

8.4.4.2.3        India Migraine Drugs Market, By Distribution Channel

8.4.4.3        Japan

8.4.4.3.1        Japan Migraine Drugs Market, By Type

8.4.4.3.1.1. Japan Abortive Medicines Market, By Type

8.4.4.3.1.2. Japan Preventive Medicines Market, By Type

8.4.4.3.2        Japan Migraine Drugs Market, By Route of Administration

8.4.4.3.3        Japan Migraine Drugs Market, By Distribution Channel

8.4.4.4        Australia

8.4.4.4.1        Australia Migraine Drugs Market, By Type

8.4.4.4.1.1. Australia Abortive Medicines Market, By Type

8.4.4.4.1.2. Australia Preventive Medicines Market, By Type

8.4.4.4.2        Australia Migraine Drugs Market, By Route of Administration

8.4.4.4.3        Australia Migraine Drugs Market, By Distribution Channel

8.4.4.5        South Korea

8.4.4.5.1        South Korea Migraine Drugs Market, By Type

8.4.4.5.1.1. South Korea Abortive Medicines Market, By Type

8.4.4.5.1.2. South Korea Preventive Medicines Market, By Type

8.4.4.5.2        South Korea Migraine Drugs Market, By Route of Administration

8.4.4.5.3        South Korea Migraine Drugs Market, By Distribution Channel

8.4.4.6        Rest of Asia-Pacific

8.4.4.6.1        Rest of Asia-Pacific Migraine Drugs Market, By Type

8.4.4.6.1.1. Rest of Asia-Pacific Abortive Medicines Market, By Type

8.4.4.6.1.2. Rest of Asia-Pacific Preventive Medicines Market, By Type

8.4.4.6.2        Rest of Asia-Pacific Migraine Drugs Market, By Route of Administration

8.4.4.6.3        Rest of Asia-Pacific Migraine Drugs Market, By Distribution Channel

8.5.           Rest of World

8.5.1             Rest of World Migraine Drugs Market, By Type

8.5.1.1        Rest of World  Abortive Medicines Market, By Type

8.5.1.2        Rest of World  Preventive Medicines Market, By Type

8.5.2             Rest of World Migraine Drugs Market, By Route of Administration

8.5.3             Rest of World Migraine Drugs Market, By Distribution Channel

8.5.4             Rest of World Migraine Drugs, Market By Country

8.5.4.1        Brazil

8.5.4.1.1        Brazil Migraine Drugs Market, By Type

8.5.4.1.1.1. Brazil Abortive Medicines Market, By Type

8.5.4.1.1.2. Brazil Preventive Medicines Market, By Type

8.5.4.1.2        Brazil Migraine Drugs Market, By Route of Administration

8.5.4.1.3        Brazil Migraine Drugs Market, By Distribution Channel

8.5.4.2        South Africa

8.5.4.2.1        South Africa Migraine Drugs Market, By Type

8.5.4.2.1.1. South Africa Abortive Medicines Market, By Type

8.5.4.2.1.2. South Africa Preventive Medicines Market, By Type

8.5.4.2.2        South Africa Migraine Drugs Market, By Route of Administration

8.5.4.2.3        South Africa Migraine Drugs Market, By Distribution Channel

8.5.4.3        Saudi Arabia

8.5.4.3.1        Saudi Arabia Migraine Drugs Market, By Type

8.5.4.3.1.1. Saudi Arabia Abortive Medicines Market, By Type

8.5.4.3.1.2. Saudi Arabia Preventive Medicines Market, By Type

8.5.4.3.2        Saudi Arabia Migraine Drugs Market, By Route of Administration

8.5.4.3.3        Saudi Arabia Migraine Drugs Market, By Distribution Channel

8.5.4.4        Remaining Countries

8.5.4.4.1        Remaining Countries Migraine Drugs Market, By Type

8.5.4.4.1.1. Remaining Countries Abortive Medicines Market, By Type

8.5.4.4.1.2. Remaining Countries Preventive Medicines Market, By Type

8.5.4.4.2        Remaining Countries Migraine Drugs Market, By Route of Administration

8.5.4.4.3        Remaining Countries Migraine Drugs Market, By Distribution Channel

9.    COMPANY PROFILES

9.1.           ABBOTT LABORATORIES

9.1.1             COMPANY OVERVIEW

9.1.2             COMPANY SNAPSHOT

9.1.3             OPERATING BUSINESS SEGMENTS

9.1.4             PRODUCT PORTFOLIO

9.1.5             BUSINESS PERFORMANCE

9.1.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.2.           ABBVIE INC.

9.2.1             COMPANY OVERVIEW

9.2.2             COMPANY SNAPSHOT

9.2.3             OPERATING BUSINESS SEGMENTS

9.2.4             PRODUCT PORTFOLIO

9.2.5             BUSINESS PERFORMANCE

9.2.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.3.           ALLERGAN PLC.

9.3.1             COMPANY OVERVIEW

9.3.2             COMPANY SNAPSHOT

9.3.3             OPERATING BUSINESS SEGMENTS

9.3.4             PRODUCT PORTFOLIO

9.3.5             BUSINESS PERFORMANCE

9.3.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.4.           ASTRAZENECA PLC

9.4.1             COMPANY OVERVIEW

9.4.2             COMPANY SNAPSHOT

9.4.3             OPERATING BUSINESS SEGMENTS

9.4.4             PRODUCT PORTFOLIO

9.4.5             BUSINESS PERFORMANCE

9.4.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.5.           EISAI CO., LTD.

9.5.1             COMPANY OVERVIEW

9.5.2             COMPANY SNAPSHOT

9.5.3             OPERATING BUSINESS SEGMENTS

9.5.4             PRODUCT PORTFOLIO

9.5.5             BUSINESS PERFORMANCE

9.5.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.6.           ENDO INTERNATIONAL PLC.

9.6.1             COMPANY OVERVIEW

9.6.2             COMPANY SNAPSHOT

9.6.3             OPERATING BUSINESS SEGMENTS

9.6.4             PRODUCT PORTFOLIO

9.6.5             BUSINESS PERFORMANCE

9.6.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.7.           GLAXOSMITHKLINE PLC.

9.7.1             COMPANY OVERVIEW

9.7.2             COMPANY SNAPSHOT

9.7.3             OPERATING BUSINESS SEGMENTS

9.7.4             PRODUCT PORTFOLIO

9.7.5             BUSINESS PERFORMANCE

9.7.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.8.           JOHNSON & JOHNSON

9.8.1             COMPANY OVERVIEW

9.8.2             COMPANY SNAPSHOT

9.8.3             OPERATING BUSINESS SEGMENTS

9.8.4             PRODUCT PORTFOLIO

9.8.5             BUSINESS PERFORMANCE

9.8.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.9.           MERCK & CO., INC.

9.9.1             COMPANY OVERVIEW

9.9.2             COMPANY SNAPSHOT

9.9.3             OPERATING BUSINESS SEGMENTS

9.9.4             PRODUCT PORTFOLIO

9.9.5             BUSINESS PERFORMANCE

9.9.6             KEY STRATEGIC MOVES AND DEVELOPMENT

9.10.         PFIZER INC.

9.10.1           COMPANY OVERVIEW

9.10.2           COMPANY SNAPSHOT

9.10.3           OPERATING BUSINESS SEGMENTS

9.10.4           PRODUCT PORTFOLIO

9.10.5           BUSINESS PERFORMANCE

9.10.6           KEY STRATEGIC MOVES AND DEVELOPMENT

LIST OF TALBES

TABLE 1.         GLOBAL MIGRAINE Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 2.         Global Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 3.         Triptans Market Value, By Region, 2019-2030, Million USD

TABLE 4.         North America Triptans Market Value, By Country, 2019-2030, Million USD

TABLE 5.         Europe Triptans Market Value, By Country, 2019-2030, Million USD

TABLE 6.         Asia-Pacific Triptans Market Value, By Country, 2019-2030, Million USD

TABLE 7.         Rest of World Triptans Market Value, By Country, 2019-2030, Million USD

TABLE 8.         Ergotamine Derivatives Market Value, By Region, 2019-2030, Million USD

TABLE 9.         North America Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

TABLE 10.       Europe Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

TABLE 11.       Asia-Pacific Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

TABLE 12.       Rest of World Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

TABLE 13.       Other Abortive Medicine Market Value, By Region, 2019-2030, Million USD

TABLE 14.       North America Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

TABLE 15.       Europe Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

TABLE 16.       Asia-Pacific Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

TABLE 17.       Rest of World Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

TABLE 18.       Abortive Medicines Market Value, By Region, 2019-2030, Million USD

TABLE 19.       North America Abortive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 20.       Europe Abortive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 21.       Asia-Pacific Abortive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 22.       Rest of World Abortive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 23.       Global Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 24.       Anticonvulsants Market Value, By Region, 2019-2030, Million USD

TABLE 25.       North America Anticonvulsants Market Value, By Country, 2019-2030, Million USD

TABLE 26.       Europe Anticonvulsants Market Value, By Country, 2019-2030, Million USD

TABLE 27.       Asia-Pacific Anticonvulsants Market Value, By Country, 2019-2030, Million USD

TABLE 28.       Rest of World Anticonvulsants Market Value, By Country, 2019-2030, Million USD

TABLE 29.       Antidepressants Market Value, By Region, 2019-2030, Million USD

TABLE 30.       North America Antidepressants Market Value, By Country, 2019-2030, Million USD

TABLE 31.       Europe Antidepressants Market Value, By Country, 2019-2030, Million USD

TABLE 32.       Asia-Pacific Antidepressants Market Value, By Country, 2019-2030, Million USD

TABLE 33.       Rest of World Antidepressants Market Value, By Country, 2019-2030, Million USD

TABLE 34.       Beta Blockers Market Value, By Region, 2019-2030, Million USD

TABLE 35.       North America Beta Blockers Market Value, By Country, 2019-2030, Million USD

TABLE 36.       Europe Beta Blockers Market Value, By Country, 2019-2030, Million USD

TABLE 37.       Asia-Pacific Beta Blockers Market Value, By Country, 2019-2030, Million USD

TABLE 38.       Rest of World Beta Blockers Market Value, By Country, 2019-2030, Million USD

TABLE 39.       Other Preventive Medicines Market Value, By Region, 2019-2030, Million USD

TABLE 40.       North America Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 41.       Europe Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 42.       Asia-Pacific Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 43.       Rest of World Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 44.       Preventive Medicines Market Value, By Region, 2019-2030, Million USD

TABLE 45.       North America Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 46.       Europe Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 47.       Asia-Pacific Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 48.       Rest of World Preventive Medicines Market Value, By Country, 2019-2030, Million USD

TABLE 49.       Global  Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 50.       Oral Market Value, By Region, 2019-2030, Million USD

TABLE 51.       North America Oral Market Value, By Country, 2019-2030, Million USD

TABLE 52.       Europe Oral Market Value, By Country, 2019-2030, Million USD

TABLE 53.       Asia-Pacific Oral Market Value, By Country, 2019-2030, Million USD

TABLE 54.       Rest of World Oral Market Value, By Country, 2019-2030, Million USD

TABLE 55.       Injection Market Value, By Region, 2019-2030, Million USD

TABLE 56.       North America Injection Market Value, By Country, 2019-2030, Million USD

TABLE 57.       Europe Injection Market Value, By Country, 2019-2030, Million USD

TABLE 58.       Asia-Pacific Injection Market Value, By Country, 2019-2030, Million USD

TABLE 59.       Rest of World Injection Market Value, By Country, 2019-2030, Million USD

TABLE 60.       Other Routes Market Value, By Region, 2019-2030, Million USD

TABLE 61.       North America Other Routes Market Value, By Country, 2019-2030, Million USD

TABLE 62.       Europe Other Routes Market Value, By Country, 2019-2030, Million USD

TABLE 63.       Asia-Pacific Other Routes Market Value, By Country, 2019-2030, Million USD

TABLE 64.       Rest of World Other Routes Market Value, By Country, 2019-2030, Million USD

TABLE 65.       Global  Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 66.       Retail Pharmacies Market Value, By Region, 2019-2030, Million USD

TABLE 67.       North America Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 68.       Europe Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 69.       Asia-Pacific Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 70.       Rest of World Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 71.       Hospital Pharmacies Market Value, By Region, 2019-2030, Million USD

TABLE 72.       North America Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 73.       Europe Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 74.       Asia-Pacific Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 75.       Rest of World Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 76.       Online Pharmacies Market Value, By Region, 2019-2030, Million USD

TABLE 77.       North America Online Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 78.       Europe Online Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 79.       Asia-Pacific Online Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 80.       Rest of World Online Pharmacies Market Value, By Country, 2019-2030, Million USD

TABLE 81.       Global  Migraine Drugs Market Value, By Region, 2019-2030, Million USD

TABLE 82.       North America Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 83.       North America  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 84.       North America  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 85.       North America Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 86.       North America Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 87.       U.S. Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 88.       U.S. Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 89.       U.S. Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 90.       U.S. Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 91.       U.S. Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 92.       Canada Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 93.       Canada Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 94.       Canada Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 95.       Canada Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 96.       Canada Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 97.       Mexico Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 98.       Mexico Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 99.       Mexico Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 100.    Mexico Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 101.    Mexico Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 102.    Europe Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 103.    Europe  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 104.    Europe  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 105.    Europe Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 106.    Europe Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 107.    Germany Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 108.    Germany Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 109.    Germany Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 110.    Germany Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 111.    Germany Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 112.    UK Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 113.    UK Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 114.    UK Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 115.    UK Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 116.    UK Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 117.    France Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 118.    France Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 119.    France Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 120.    France Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 121.    France Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 122.    Italy Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 123.    Italy Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 124.    Italy Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 125.    Italy Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 126.    Italy Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 127.    Spain Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 128.    Spain Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 129.    Spain Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 130.    Spain Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 131.    Spain Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 132.    Rest of Europe Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 133.    Rest of Europe Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 134.    Rest of Europe Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 135.    Rest of Europe Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 136.    Rest of Europe Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 137.    Asia-Pacific Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 138.    Asia-Pacific  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 139.    Asia-Pacific  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 140.    Asia-Pacific Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 141.    Asia-Pacific Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 142.    China Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 143.    China Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 144.    China Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 145.    China Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 146.    China Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 147.    India Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 148.    India Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 149.    India Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 150.    India Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 151.    India Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 152.    Japan Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 153.    Japan Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 154.    Japan Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 155.    Japan Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 156.    Japan Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 157.    Australia Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 158.    Australia Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 159.    Australia Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 160.    Australia Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 161.    Australia Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 162.    South Korea Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 163.    South Korea Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 164.    South Korea Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 165.    South Korea Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 166.    South Korea Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 167.    Rest of Asia-Pacific Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 168.    Rest of Asia-Pacific Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 169.    Rest of Asia-Pacific Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 170.    Rest of Asia-Pacific Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 171.    Rest of Asia-Pacific Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 172.    Rest of World Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 173.    Rest of World  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 174.    Rest of World  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 175.    Rest of World Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 176.    Rest of World Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 177.    Brazil Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 178.    Brazil Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 179.    Brazil Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 180.    Brazil Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 181.    Brazil Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 182.    South Africa Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 183.    South Africa Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 184.    South Africa Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 185.    South Africa Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 186.    South Africa Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 187.    Saudi Arabia Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 188.    Saudi Arabia Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 189.    Saudi Arabia Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 190.    Saudi Arabia Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 191.    Saudi Arabia Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 192.    Remaining Countries Migraine Drugs Market Value, By Type, 2019-2030, Million USD

TABLE 193.    Remaining Countries Abortive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 194.    Remaining Countries Preventive Medicines Market Value, By Type, 2019-2030, Million USD

TABLE 195.    Remaining Countries Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

TABLE 196.    Remaining Countries Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

TABLE 197.    ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 198.    ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 199.    ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 200.    ABBOTT LABORATORIES: KEY STRATERGY

TABLE 201.    ABBVIE INC.: COMPANY SNAPSHOT

TABLE 202.    ABBVIE INC.: OPERATING SEGMENTS

TABLE 203.    ABBVIE INC.: PRODUCT PORTFOLIO

TABLE 204.    ABBVIE INC.: KEY STRATERGY

TABLE 205.    ALLERGAN PLC.: COMPANY SNAPSHOT

TABLE 206.    ALLERGAN PLC.: OPERATING SEGMENTS

TABLE 207.    ALLERGAN PLC.: PRODUCT PORTFOLIO

TABLE 208.    ALLERGAN PLC.: KEY STRATERGY

TABLE 209.    ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 210.    ASTRAZENECA PLC: OPERATING SEGMENTS

TABLE 211.    ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 212.    ASTRAZENECA PLC: KEY STRATERGY

TABLE 213.    EISAI CO., LTD.: COMPANY SNAPSHOT

TABLE 214.    EISAI CO., LTD.: OPERATING SEGMENTS

TABLE 215.    EISAI CO., LTD.: PRODUCT PORTFOLIO

TABLE 216.    EISAI CO., LTD.: KEY STRATERGY

TABLE 217.    ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT

TABLE 218.    ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS

TABLE 219.    ENDO INTERNATIONAL PLC.: PRODUCT PORTFOLIO

TABLE 220.    ENDO INTERNATIONAL PLC.: KEY STRATERGY

TABLE 221.    GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT

TABLE 222.    GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS

TABLE 223.    GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO

TABLE 224.    GLAXOSMITHKLINE PLC.: KEY STRATERGY

TABLE 225.    JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 226.    JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 227.    JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 228.    JOHNSON & JOHNSON: KEY STRATERGY

TABLE 229.    MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 230.    MERCK & CO., INC.: OPERATING SEGMENTS

TABLE 231.    MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 232.    MERCK & CO., INC.: KEY STRATERGY

TABLE 233.    PFIZER INC.: COMPANY SNAPSHOT

TABLE 234.    PFIZER INC.: OPERATING SEGMENTS

TABLE 235.    PFIZER INC.: PRODUCT PORTFOLIO

TABLE 236.    PFIZER INC.: KEY STRATERGY

 

 

LIST OF FIGURES

FIGURE 1.       Global  Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 2.       Global Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 3.       Triptans Market Value, By Region, 2019-2030, Million USD

FIGURE 4.       North America Triptans Market Value, By Country, 2019-2030, Million USD

FIGURE 5.       Europe Triptans Market Value, By Country, 2019-2030, Million USD

FIGURE 6.       Asia-Pacific Triptans Market Value, By Country, 2019-2030, Million USD

FIGURE 7.       Rest of World Triptans Market Value, By Country, 2019-2030, Million USD

FIGURE 8.       Ergotamine Derivatives Market Value, By Region, 2019-2030, Million USD

FIGURE 9.       North America Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

FIGURE 10.     Europe Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

FIGURE 11.     Asia-Pacific Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

FIGURE 12.     Rest of World Ergotamine Derivatives Market Value, By Country, 2019-2030, Million USD

FIGURE 13.     Other Abortive Medicine Market Value, By Region, 2019-2030, Million USD

FIGURE 14.     North America Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

FIGURE 15.     Europe Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

FIGURE 16.     Asia-Pacific Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

FIGURE 17.     Rest of World Other Abortive Medicine Market Value, By Country, 2019-2030, Million USD

FIGURE 18.     Abortive Medicines Market Value, By Region, 2019-2030, Million USD

FIGURE 19.     North America Abortive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 20.     Europe Abortive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 21.     Asia-Pacific Abortive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 22.     Rest of World Abortive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 23.     Global Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 24.     Anticonvulsants Market Value, By Region, 2019-2030, Million USD

FIGURE 25.     North America Anticonvulsants Market Value, By Country, 2019-2030, Million USD

FIGURE 26.     Europe Anticonvulsants Market Value, By Country, 2019-2030, Million USD

FIGURE 27.     Asia-Pacific Anticonvulsants Market Value, By Country, 2019-2030, Million USD

FIGURE 28.     Rest of World Anticonvulsants Market Value, By Country, 2019-2030, Million USD

FIGURE 29.     Antidepressants Market Value, By Region, 2019-2030, Million USD

FIGURE 30.     North America Antidepressants Market Value, By Country, 2019-2030, Million USD

FIGURE 31.     Europe Antidepressants Market Value, By Country, 2019-2030, Million USD

FIGURE 32.     Asia-Pacific Antidepressants Market Value, By Country, 2019-2030, Million USD

FIGURE 33.     Rest of World Antidepressants Market Value, By Country, 2019-2030, Million USD

FIGURE 34.     Beta Blockers Market Value, By Region, 2019-2030, Million USD

FIGURE 35.     North America Beta Blockers Market Value, By Country, 2019-2030, Million USD

FIGURE 36.     Europe Beta Blockers Market Value, By Country, 2019-2030, Million USD

FIGURE 37.     Asia-Pacific Beta Blockers Market Value, By Country, 2019-2030, Million USD

FIGURE 38.     Rest of World Beta Blockers Market Value, By Country, 2019-2030, Million USD

FIGURE 39.     Other Preventive Medicines Market Value, By Region, 2019-2030, Million USD

FIGURE 40.     North America Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 41.     Europe Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 42.     Asia-Pacific Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 43.     Rest of World Other Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 44.     Preventive Medicines Market Value, By Region, 2019-2030, Million USD

FIGURE 45.     North America Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 46.     Europe Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 47.     Asia-Pacific Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 48.     Rest of World Preventive Medicines Market Value, By Country, 2019-2030, Million USD

FIGURE 49.     Global  Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 50.     Oral Market Value, By Region, 2019-2030, Million USD

FIGURE 51.     North America Oral Market Value, By Country, 2019-2030, Million USD

FIGURE 52.     Europe Oral Market Value, By Country, 2019-2030, Million USD

FIGURE 53.     Asia-Pacific Oral Market Value, By Country, 2019-2030, Million USD

FIGURE 54.     Rest of World Oral Market Value, By Country, 2019-2030, Million USD

FIGURE 55.     Injection Market Value, By Region, 2019-2030, Million USD

FIGURE 56.     North America Injection Market Value, By Country, 2019-2030, Million USD

FIGURE 57.     Europe Injection Market Value, By Country, 2019-2030, Million USD

FIGURE 58.     Asia-Pacific Injection Market Value, By Country, 2019-2030, Million USD

FIGURE 59.     Rest of World Injection Market Value, By Country, 2019-2030, Million USD

FIGURE 60.     Other Routes Market Value, By Region, 2019-2030, Million USD

FIGURE 61.     North America Other Routes Market Value, By Country, 2019-2030, Million USD

FIGURE 62.     Europe Other Routes Market Value, By Country, 2019-2030, Million USD

FIGURE 63.     Asia-Pacific Other Routes Market Value, By Country, 2019-2030, Million USD

FIGURE 64.     Rest of World Other Routes Market Value, By Country, 2019-2030, Million USD

FIGURE 65.     Global  Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 66.     Retail Pharmacies Market Value, By Region, 2019-2030, Million USD

FIGURE 67.     North America Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 68.     Europe Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 69.     Asia-Pacific Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 70.     Rest of World Retail Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 71.     Hospital Pharmacies Market Value, By Region, 2019-2030, Million USD

FIGURE 72.     North America Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 73.     Europe Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 74.     Asia-Pacific Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 75.     Rest of World Hospital Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 76.     Online Pharmacies Market Value, By Region, 2019-2030, Million USD

FIGURE 77.     North America Online Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 78.     Europe Online Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 79.     Asia-Pacific Online Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 80.     Rest of World Online Pharmacies Market Value, By Country, 2019-2030, Million USD

FIGURE 81.     Global  Migraine Drugs Market Value, By Region, 2019-2030, Million USD

FIGURE 82.     North America Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 83.     North America  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 84.     North America  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 85.     North America Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 86.     North America Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 87.     U.S. Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 88.     U.S. Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 89.     U.S. Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 90.     U.S. Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 91.     U.S. Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 92.     Canada Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 93.     Canada Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 94.     Canada Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 95.     Canada Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 96.     Canada Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 97.     Mexico Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 98.     Mexico Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 99.     Mexico Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 100.  Mexico Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 101.  Mexico Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 102.  Europe Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 103.  Europe  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 104.  Europe  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 105.  Europe Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 106.  Europe Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 107.  Germany Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 108.  Germany Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 109.  Germany Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 110.  Germany Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 111.  Germany Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 112.  UK Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 113.  UK Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 114.  UK Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 115.  UK Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 116.  UK Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 117.  France Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 118.  France Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 119.  France Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 120.  France Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 121.  France Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 122.  Italy Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 123.  Italy Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 124.  Italy Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 125.  Italy Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 126.  Italy Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 127.  Spain Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 128.  Spain Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 129.  Spain Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 130.  Spain Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 131.  Spain Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 132.  Rest of Europe Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 133.  Rest of Europe Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 134.  Rest of Europe Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 135.  Rest of Europe Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 136.  Rest of Europe Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 137.  Asia-Pacific Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 138.  Asia-Pacific  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 139.  Asia-Pacific  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 140.  Asia-Pacific Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 141.  Asia-Pacific Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 142.  China Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 143.  China Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 144.  China Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 145.  China Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 146.  China Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 147.  India Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 148.  India Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 149.  India Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 150.  India Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 151.  India Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 152.  Japan Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 153.  Japan Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 154.  Japan Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 155.  Japan Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 156.  Japan Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 157.  Australia Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 158.  Australia Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 159.  Australia Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 160.  Australia Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 161.  Australia Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 162.  South Korea Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 163.  South Korea Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 164.  South Korea Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 165.  South Korea Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 166.  South Korea Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 167.  Rest of Asia-Pacific Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 168.  Rest of Asia-Pacific Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 169.  Rest of Asia-Pacific Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 170.  Rest of Asia-Pacific Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 171.  Rest of Asia-Pacific Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 172.  Rest of World Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 173.  Rest of World  Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 174.  Rest of World  Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 175.  Rest of World Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 176.  Rest of World Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 177.  Brazil Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 178.  Brazil Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 179.  Brazil Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 180.  Brazil Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 181.  Brazil Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 182.  South Africa Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 183.  South Africa Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 184.  South Africa Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 185.  South Africa Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 186.  South Africa Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 187.  Saudi Arabia Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 188.  Saudi Arabia Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 189.  Saudi Arabia Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 190.  Saudi Arabia Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 191.  Saudi Arabia Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 192.  Remaining Countries Migraine Drugs Market Value, By Type, 2019-2030, Million USD

FIGURE 193.  Remaining Countries Abortive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 194.  Remaining Countries Preventive Medicines Market Value, By Type, 2019-2030, Million USD

FIGURE 195.  Remaining Countries Migraine Drugs Market Value, By Route of Administration, 2019-2030, Million USD

FIGURE 196.  Remaining Countries Migraine Drugs Market Value, By Distribution Channel, 2019-2030, Million USD

FIGURE 197.  ABBOTT LABORATORIES: NET SALES,2017-2019

FIGURE 198.  ABBVIE INC.: NET SALES,2017-2019

FIGURE 199.  ALLERGAN PLC.: NET SALES,2017-2019

FIGURE 200.  ASTRAZENECA PLC: NET SALES,2017-2019

FIGURE 201.  EISAI CO., LTD.: NET SALES,2017-2019

FIGURE 202.  ENDO INTERNATIONAL PLC.: NET SALES,2017-2019

FIGURE 203.  GLAXOSMITHKLINE PLC.: NET SALES,2017-2019

FIGURE 204.  JOHNSON & JOHNSON: NET SALES,2017-2019

FIGURE 205.  MERCK & CO., INC.: NET SALES,2017-2019

FIGURE 206.  PFIZER INC.: NET SALES,2017-2019

KEY PLAYERS:

  • Abbott Laboratories
  • Abbvie Inc
  • Allergan Plc
  • Astrazeneca Plc
  • Eisai Co., Ltd
  • Endo International Plc
  • Glaxosmithkline Plc
  • Johnson & Johnson
  • Merck & Co., Inc
  • Pfizer Inc

Frequently Asked Questions
What will be the worth of global Migraine Drugs Market by the end of 2030?

According to the report published by Next Move Strategy Consulting, the Migraine Drugs market business is expected to hit at $2.44 billion (USD) by 2030.

Which region is expected to hold the highest market share in the Migraine Drugs Market?

North America is expected to hold the highest market share in the global market. The region is expected to witness remarkable growth as it houses the major key players in the market.

Which are the top companies in the Migraine Drugs industry?

Allergan Plc., Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA, and Novartis International AG

What are the market segmentations and scope of the study?

The global Migraine Drugs market share is analyzed on the basis of type, route of administration, distribution channel and geography.

How big is the Migraine Drugs market?

Currently (in 2019), the market value stands at USD 1.80 billion and it is anticipated to reach USD 2.44 billion by 2030.